Alpha 2.0
Login Register
» Articles » PMID: 36119181

Resurgence of Hypertension and Cardiovascular Diseases in Patients Recovered from COVID-19: An Indian Perspective

Overview
Journal J Family Med Prim Care
Specialty Public Health
Date 2022 Sep 19
PMID 36119181
Authors
Bhaskaran Krishnakumar
Johann Christopher
P Sunil Prasobh
Shreerang Godbole
Anurag Mehrotra
Anurag Singhal
Satrajit Roy
Kuntal Bhattacharya
Narendra Kolte
Mahesh V Abhyankar
Santosh Revankar
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to understand the prevalence, extent, clinical approach of hypertension and cardiovascular disease (CVD) in patients recovered from COVID-19.

Methods: The round table meetings (RTMs) and survey convened a diverse panel of specialists including cardiologists, endocrinologists, diabetologists, consultant physicians, and family physicians from various geographical zones of India. A standard questionnaire including 10 questions was developed pertaining to the resurgence of hypertension and CVD in patients recovered from COVID-19. The RTMs and survey were held virtually. The collected opinions and recommendations were compiled to derive a consensus document.

Results: A total of 3066 health-care practitioners (HCPs) participated. Hypertension was the most prevalent comorbidity in patients recovered from COVID-19 followed by diabetes, dyslipidemia, and coronary artery disease. Almost two-thirds of HCPs reported that 10%-30% newly diagnosed hypertension in patients recovered from COVID-19. Uncontrolled hypertension in 10-20% of COVID-19 recovered patients opined by 45% of the HCPs. About, 35% HCPs reported CV complications in 10-20% of Covid-19 recovered patients and 63% HCPs reported exacerbations of CAD in 10-30% of patients. Majority of HCPs preferred to switch to dual combination therapy from monotherapy for hypertension management (52.0%) and ARBs and its combination is most preferred combination for hypertension control (60%). Majority of the HCPs suggested follow-up after 1-2 weeks (39.0%). Close monitoring on symptoms including chest pain and breathlessness (45.0%), adherence to medication and regular monitoring of lab parameters (25%) is recommended for these patients.

Conclusion: Overall observations indicate an increased incidence of hypertension and CVDs post recovery from COVID-19. A dual therapy of ARBs was the preferred choice for management of hypertension. Regular follow-up and close monitoring of symptoms to prevent further CV complications in COVID-19 recovered patients is recommended.

References
1.
Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T . Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020; 43(10):1028-1046. PMC: 7393334. DOI: 10.1038/s41440-020-0515-0. View
2.
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J . Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020; 9(1):757-760. PMC: 7170368. DOI: 10.1080/22221751.2020.1746200. View
3.
Saeed O, Castagna F, Agalliu I, Xue X, Patel S, Rochlani Y . Statin Use and In-Hospital Mortality in Patients With Diabetes Mellitus and COVID-19. J Am Heart Assoc. 2020; 9(24):e018475. PMC: 7955378. DOI: 10.1161/JAHA.120.018475. View
4.
Zhao Y, Shang Y, Song W, Li Q, Xie H, Xu Q . Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020; 25:100463. PMC: 7361108. DOI: 10.1016/j.eclinm.2020.100463. View
5.
. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018; 6(12):e1339-e1351. PMC: 6227386. DOI: 10.1016/S2214-109X(18)30407-8. View